Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04654208

Swedish Ibrance Registries Insights (SIRI)

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Malignant Neoplasm of Breast Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pfizer Sweden

Sollentuna, Sweden

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  • One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
  • Age ≥18 years at index date

Exclusion criteria

There are no exclusion criteria

Treatment and study plan

Palbociclib

Drug

patients on palbociclib combination treatment

Primary outcomes

  1. Proportion of patients on treatment

    Time frame: 01 January 2017 until 30 September 2020

    Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study [assessed up to 48 months])

Secondary outcomes

  1. Proportion of patients alive

    Time frame: 01 January 2017 until 30 September 2020

    Proportion of patients alive on palbociclib combination treatment at different points in time (Time Frame: treatment start date through end of study [assessed up to 48 months])

  2. Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment

    Time frame: 01 January 2017 until 30 September 2020

Study contacts

Contact information is provided by the study sponsor or research team.

Pfizer CT.gov Call Center

CONTACT

[email protected]

1-800-718-1021

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)

Acronym: SIRI

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Dec 4, 2020
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.